Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ustekinumab for moderate-to-severe Crohn's disease.

Ustekinumab for moderate-to-severe Crohn's disease. Gastroenterology. 2013 Apr; 144(4):846-8.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.